Company intelligence / Profile preview
Biomissile Pharmaceuticals Co., Ltd.
Shanghai, Shanghai, Chinabiomissile.com ↗
- Ownership
- Private
- Development stage
- Phase 2
01
Overview
Currently conducting a Phase I, multicenter, non-randomized, open-label study to evaluate the safety, tolerability, pharmacokinetics, and efficacy of BM230 in patients with advanced solid tumors. The company has two leading projects in clinical stages (Phase I & II) and a third one in IND filing stage.
- Therapeutic areas
- OncologyPulmonologyImmunologyGastroenterologyInfectious Diseases
- Modalities
- Multi-specific therapeutic antibodiesFully human domain antibodiesBispecific antibodiesMonoclonal antibodies
- Industry
- Biotech
02
Drug pipeline
10 assets9 more assets in the full pipeline.
Beyond the preview
Go deeper on Biomissile Pharmaceuticals Co., Ltd..
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Biomissile Pharmaceuticals Co., Ltd..